FTSE MIB
34.490,71 +23,04 (+0,07%) Dow Jones
39.069,59 +4,33 (+0,01%) Nasdaq
16.920,79 +184,76 (+1,10%) Nikkei 225
38.646,11 -457,11 (-1,17%) Petrolio
77,80 +0,93 (+1,21%) Bitcoin EUR
63.902,09 +378,25 (+0,60%)
Mineralys Therapeutics, Inc. (MLYS)
Dopo ore:
| Chiusura precedente | 12,23 |
| Aperto | 12,20 |
| Denaro | 12,15 x 200 |
| Domanda | 12,23 x 200 |
| Min-Max giorno | 12,00 - 12,22 |
| Intervallo di 52 settimane | 5,85 - 17,44 |
| Volume | |
| Media Volume | 136.892 |
| Capitalizzazione | 605,712M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,18 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 33,50 |
GlobeNewswireMineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
Late-breaking poster presentation at ASN’s Kidney Week 2023 - - -Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced upcoming poster presentations at two scientific conferences being held in November
GlobeNewswirePraxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy
Adam Levy Appointment to Board of Directors LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch (“Praxis”), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer’s Disease, today announced the appointment of Adam Levy to its Board of Directors (the “Board”). Mr. Levy brings executive, financial and operational leadership experience in biopharmace
GlobeNewswireMineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas
Daphne Karydas Daphne Karydas Glenn Sblendorio Glenn Sblendorio RADNOR, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointments of Daphne Karydas and Glenn Sblendorio to its Board of Directors (the Board). Ms. Karydas and Mr. Sblendorio bring execu
